Respiratory Syncytial Virus Diagnostics Market Size, Share & Trends Analysis Report By Product (DFA, RADT, Molecular Diagnostics, Chromatographic Immunoassay), By End Use, By Region, And Segment Forecasts, 2025 - 2030
This report can be delivered to the clients within 3 Business Days
Respiratory Syncytial Virus Diagnostics Market Growth & Trends
The global respiratory syncytial virus diagnostics market size is estimated treach USD 8.70 billion by 2030, expanding at a CAGR of 5.81% from 2025 t2030, according ta new report by Grand View Research, Inc. Increasing neonatal population suffering from respiratory conditions including RSV infections and supportive initiatives for diagnosis of newborns by the healthcare providers are expected tbe vital impact rendering drivers for RSV diagnostics market.
According tthe statistics provided by the WHO, hospitalization of over 150,000 children (below the age of five) and about 14,000 deaths in geriatric patients occurred in the U.S. in 2014 due tRSV infections. This is anticipated ttrigger demand for testing of these conditions over the forecast period.
Furthermore, the global birth rate as of 2014 is 18.7 births per 1,000 individuals, which is predicted tincrease the infant population substantially over the next seven years. According tthe statistics, it is estimated that about 134.2 million births took place in 2014, which are prone tRSV infections and require diagnosis, thus forming a large market base.
In 2010, Save Babies Through Screening Foundation (SBTS) entered in a partnership with World Solutions Against Infectious Disease (WSAID) as an attempt tpromote higher screening of newborns for infectious diseases, metabolic disorders, and hearing disabilities.
Respiratory Syncytial Virus Diagnostics Market Report Highlights
Respiratory Syncytial Virus Diagnostics Market Growth & Trends
The global respiratory syncytial virus diagnostics market size is estimated treach USD 8.70 billion by 2030, expanding at a CAGR of 5.81% from 2025 t2030, according ta new report by Grand View Research, Inc. Increasing neonatal population suffering from respiratory conditions including RSV infections and supportive initiatives for diagnosis of newborns by the healthcare providers are expected tbe vital impact rendering drivers for RSV diagnostics market.
According tthe statistics provided by the WHO, hospitalization of over 150,000 children (below the age of five) and about 14,000 deaths in geriatric patients occurred in the U.S. in 2014 due tRSV infections. This is anticipated ttrigger demand for testing of these conditions over the forecast period.
Furthermore, the global birth rate as of 2014 is 18.7 births per 1,000 individuals, which is predicted tincrease the infant population substantially over the next seven years. According tthe statistics, it is estimated that about 134.2 million births took place in 2014, which are prone tRSV infections and require diagnosis, thus forming a large market base.
In 2010, Save Babies Through Screening Foundation (SBTS) entered in a partnership with World Solutions Against Infectious Disease (WSAID) as an attempt tpromote higher screening of newborns for infectious diseases, metabolic disorders, and hearing disabilities.
Respiratory Syncytial Virus Diagnostics Market Report Highlights
- Chromatographic immunoassay segment dominated the market with a share of 27.38% in 2024 over the next seven years owing ttheir higher specificity than molecular diagnostic products. The commercially available test kits include Binax Now RSV, QuickLab RSV Test, Remel Xpect, and RSV Respi-Strip.
- Hospitals segment dominated the market with a share of 41.09% in 2024 and is anticipated tgrow at fastest growth rate over the forecast period. Increasing demand for home care diagnostic devices by patients is anticipated tdrive growth of the segment over the next seven years.
- North America is anticipated tdominate the market and contribute a revenue share of over 41.18% by 2024. Rising awareness among the population base and favorable initiatives by the government agencies such as the WHO, PAHO, and WSAID tinitiate and implement newborn screening are expected tdrive growth.
- Key players of the market include Novartis AG, Abbott, BD and Company, OrthClinical Diagnostics, Roche Diagnostics, Abbott Laboratories, and ThermFisher Scientific Inc. CLIA waiver and launch of RSV assays by companies like Roche Diagnostics, Becton Dickinson and Company, and Alere Inc. are expected tboost market growth over the forecast period.
CHAPTER 1. METHODOLOGY AND SCOPE
1.1. Market Segmentation & Scope
1.2. Segment Definitions
1.2.1. Product
1.2.2. End use
1.2.3. Regional scope
1.2.4. Estimates and forecasts timeline
1.3. Research Methodology
1.4. Information Procurement
1.4.1. Purchased database
1.4.2. GVR’s internal database
1.4.3. Secondary sources
1.4.4. Primary research
1.4.5. Details of primary research
1.4.5.1. Data for primary interviews in North America
1.4.5.2. Data for primary interviews in Europe
1.4.5.3. Data for primary interviews in Asia Pacific
1.4.5.4. Data for primary interviews in Latin America
1.4.5.5. Data for Primary interviews in MEA
1.5. Information or Data Analysis
1.5.1. Data analysis models
1.6. Market Formulation & Validation
1.7. Model Details
1.7.1. Commodity flow analysis (Model 1)
1.7.2. Approach 1: Commodity flow approach
1.7.3. Volume price analysis (Model 2)
1.7.4. Approach 2: Volume price analysis
1.8. List of Secondary Sources
1.9. List of Primary Sources
1.10. Objectives
CHAPTER 2. EXECUTIVE SUMMARY
2.1. Market Outlook
2.2. Segment Outlook
2.2.1. Product and End use outlook
2.2.2. Regional outlook
2.3. Competitive Insights
CHAPTER 3. RESPIRATORY SYNCYTIAL VIRUS DIAGNOSTICS MARKET VARIABLES, TRENDS & SCOPE
3.1. Market Lineage Outlook
3.1.1. Parent market outlook
3.1.2. Related/ancillary market outlook
3.2. Market Dynamics
3.2.1. Market driver analysis
3.2.1.1. Rising prevalence of Respiratory Syncytial Virus (RSV) Infections
3.2.1.2. Advancements in diagnostics technologies
3.2.1.3. Growing awareness and healthcare spending
3.2.2. Market restraint analysis
3.2.2.1. High cost associated with advanced diagnostic tests
3.2.2.2. Lack of awareness in developing reagions
3.3. Respiratory Syncytial Virus Diagnostics Market Analysis Tools
3.3.1. Industry Analysis - Porter’s
3.3.1.1. Supplier power
3.3.1.2. Buyer power
3.3.1.3. Substitution threat
3.3.1.4. Threat of new entrant
3.3.1.5. Competitive rivalry
3.3.2. PESTEL Analysis
3.3.2.1. Political landscape
3.3.2.2. Economic landscape
3.3.2.3. Technological landscape
3.3.2.4. Social landscape
3.3.2.5. Environmental landscape
CHAPTER 4. RESPIRATORY SYNCYTIAL VIRUS DIAGNOSTICS MARKET: PRODUCT ESTIMATES & TREND ANALYSIS
4.1. Global Respiratory Syncytial Virus Diagnostics Market: Product Dashboard
4.2. Global Respiratory Syncytial Virus Diagnostics Market: Product Movement Analysis
4.3. Global Respiratory Syncytial Virus Diagnostics Market by Product , Revenue
4.4. Direct Fluorescent Antibody (DFA) Method
4.5. Rapid Antigen Diagnostic Test (RADTs)
4.5.1. Rapid Antigen Diagnostic Test (RADTs) market estimates and forecasts 2018 to 2030 (USD Billion)
4.6. Molecular Diagnostics
4.6.1. Molecular diagnostics market estimates and forecasts 2018 to 2030 (USD Billion)
4.7. Chromatographic Immunoassay
4.7.1. Chromatography immunoassay market estimates and forecasts 2018 to 2030 (USD Billion)
4.7.2. Gravity Driven Test
4.7.2.1. Gravity driven test market estimates and forecasts 2018 to 2030 (USD Billion)
4.7.3. Oligochromatography (OC)
4.7.3.1. Oligochromatography (OC) market estimates and forecasts 2018 to 2030 (USD Billion)
4.8. Diagnostic Imaging
4.8.1. Diagnostic imaging market estimates and forecasts 2018 to 2030 (USD Billion)
4.9. Gel Microdroplets
4.9.1. Gel microdroplets market estimates and forecasts 2018 to 2030 (USD Billion)
4.10. Flow Cytometry
4.10.1. Flow cytometry market estimates and forecasts 2018 to 2030 (USD Billion)
4.11. Others
4.11.1. Others market estimates and forecasts 2018 to 2030 (USD Billion)
CHAPTER 5. RESPIRATORY SYNCYTIAL VIRUS DIAGNOSTICS MARKET: END USE ESTIMATES & TREND ANALYSIS
5.1. Global Respiratory Syncytial Virus Diagnostics Market: End use Dashboard
5.2. Global Respiratory Syncytial Virus Diagnostics Market: End use Movement Analysis
5.3. Global Respiratory Syncytial Virus Diagnostics Market by End use, Revenue
5.4. Hospitals
5.4.1. Hospitals market estimates and forecasts 2018 to 2030 (USD Billion)
5.5. Laboratory
5.5.1. Laboratory market estimates and forecasts 2018 to 2030 (USD Billion)
5.6. Clinics
5.6.1. Clinics market estimates and forecasts 2018 to 2030 (USD Billion)
5.7. Others
5.7.1. Others market estimates and forecasts 2018 to 2030 (USD Billion)
CHAPTER 6. RESPIRATORY SYNCYTIAL VIRUS DIAGNOSTICS MARKET: REGIONAL ESTIMATES & TREND ANALYSIS BY TYPE, TUBE MATERIAL, APPLICATION, AND END USE
6.1. Regional Dashboard
6.2. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
6.3. North America
6.3.1. U.S.
6.3.1.1. Key country dynamics
6.3.1.2. Regulatory framework/ reimbursement structure
6.3.1.3. Competitive scenario
6.3.1.4. U.S. market estimates and forecasts 2018 to 2030 (USD Billion)
6.3.2. Canada
6.3.2.1. Key country dynamics
6.3.2.2. Regulatory framework/ reimbursement structure
6.3.2.3. Competitive scenario
6.3.2.4. Canada market estimates and forecasts 2018 to 2030 (USD Billion)
6.3.3. Mexico
6.3.3.1. Key country dynamics
6.3.3.2. Regulatory framework/ reimbursement structure
6.3.3.3. Competitive scenario
6.3.3.4. Mexico market estimates and forecasts 2018 to 2030 (USD Billion)
6.4. Europe
6.4.1. UK
6.4.1.1. Key country dynamics
6.4.1.2. Regulatory framework/ reimbursement structure
6.4.1.3. Competitive scenario
6.4.1.4. UK market estimates and forecasts 2018 to 2030 (USD Billion)
6.4.2. Germany
6.4.2.1. Key country dynamics
6.4.2.2. Regulatory framework/ reimbursement structure
6.4.2.3. Competitive scenario
6.4.2.4. Germany market estimates and forecasts 2018 to 2030 (USD Billion)
6.4.3. France
6.4.3.1. Key country dynamics
6.4.3.2. Regulatory framework/ reimbursement structure
6.4.3.3. Competitive scenario
6.4.3.4. France market estimates and forecasts 2018 to 2030 (USD Billion)
6.4.4. Italy
6.4.4.1. Key country dynamics
6.4.4.2. Regulatory framework/ reimbursement structure
6.4.4.3. Competitive scenario
6.4.4.4. Italy market estimates and forecasts 2018 to 2030 (USD Billion)
6.4.5. Spain
6.4.5.1. Key country dynamics
6.4.5.2. Regulatory framework/ reimbursement structure
6.4.5.3. Competitive scenario
6.4.5.4. Spain market estimates and forecasts 2018 to 2030 (USD Billion)
6.4.6. Norway
6.4.6.1. Key country dynamics
6.4.6.2. Regulatory framework/ reimbursement structure
6.4.6.3. Competitive scenario
6.4.6.4. Norway market estimates and forecasts 2018 to 2030 (USD Billion)
6.4.7. Sweden
6.4.7.1. Key country dynamics
6.4.7.2. Regulatory framework/ reimbursement structure
6.4.7.3. Competitive scenario
6.4.7.4. Sweden market estimates and forecasts 2018 to 2030 (USD Billion)
6.4.8. Denmark
6.4.8.1. Key country dynamics
6.4.8.2. Regulatory framework/ reimbursement structure
6.4.8.3. Competitive scenario
6.4.8.4. Denmark market estimates and forecasts 2018 to 2030 (USD Billion)
6.5. Asia Pacific
6.5.1. Japan
6.5.1.1. Key country dynamics
6.5.1.2. Regulatory framework/ reimbursement structure
6.5.1.3. Competitive scenario
6.5.1.4. Japan market estimates and forecasts 2018 to 2030 (USD Billion)
6.5.2. China
6.5.2.1. Key country dynamics
6.5.2.2. Regulatory framework/ reimbursement structure
6.5.2.3. Competitive scenario
6.5.2.4. China market estimates and forecasts 2018 to 2030 (USD Billion)
6.5.3. India
6.5.3.1. Key country dynamics
6.5.3.2. Regulatory framework/ reimbursement structure
6.5.3.3. Competitive scenario
6.5.3.4. India market estimates and forecasts 2018 to 2030 (USD Billion)
6.5.4. Australia
6.5.4.1. Key country dynamics
6.5.4.2. Regulatory framework/ reimbursement structure
6.5.4.3. Competitive scenario
6.5.4.4. Australia market estimates and forecasts 2018 to 2030 (USD Billion)
6.5.5. South Korea
6.5.5.1. Key country dynamics
6.5.5.2. Regulatory framework/ reimbursement structure
6.5.5.3. Competitive scenario
6.5.5.4. South Korea market estimates and forecasts 2018 to 2030 (USD Billion)
6.5.6. Thailand
6.5.6.1. Key country dynamics
6.5.6.2. Regulatory framework/ reimbursement structure
6.5.6.3. Competitive scenario
6.5.6.4. Thailand market estimates and forecasts 2018 to 2030 (USD Billion)
6.6. Latin America
6.6.1. Brazil
6.6.1.1. Key country dynamics
6.6.1.2. Regulatory framework/ reimbursement structure
6.6.1.3. Competitive scenario
6.6.1.4. Brazil market estimates and forecasts 2018 to 2030 (USD Billion)
6.6.2. Argentina
6.6.2.1. Key country dynamics
6.6.2.2. Regulatory framework/ reimbursement structure
6.6.2.3. Competitive scenario
6.6.2.4. Argentina market estimates and forecasts 2018 to 2030 (USD Billion)
6.7. MEA
6.7.1. South Africa
6.7.1.1. Key country dynamics
6.7.1.2. Regulatory framework/ reimbursement structure
6.7.1.3. Competitive scenario
6.7.1.4. South Africa market estimates and forecasts 2018 to 2030 (USD Billion)
6.7.2. Saudi Arabia
6.7.2.1. Key country dynamics
6.7.2.2. Regulatory framework/ reimbursement structure
6.7.2.3. Competitive scenario
6.7.2.4. Saudi Arabia market estimates and forecasts 2018 to 2030 (USD Billion)
6.7.3. UAE
6.7.3.1. Key country dynamics
6.7.3.2. Regulatory framework/ reimbursement structure
6.7.3.3. Competitive scenario
6.7.3.4. UAE market estimates and forecasts 2018 to 2030 (USD Billion)
6.7.4. Kuwait
6.7.4.1. Key country dynamics
6.7.4.2. Regulatory framework/ reimbursement structure
6.7.4.3. Competitive scenario
6.7.4.4. Kuwait market estimates and forecasts 2018 to 2030 (USD Billion)
CHAPTER 7. COMPETITIVE LANDSCAPE
7.1. Recent Developments & Impact Analysis, By Key Market Participants
7.2. Company/Competition Categorization
7.3. Vendor Landscape
7.3.1. List of key distributors and channel partners
7.3.2. Key customers
7.3.3. Key company market share analysis, 2024
7.3.4. BD (Becton, Dickinson, and Company)
7.3.4.1. Company overview
7.3.4.2. Financial performance
7.3.4.3. Product benchmarking
7.3.4.4. Strategic initiatives
7.3.5. Novartis AG
7.3.5.1. Company overview
7.3.5.2. Financial performance
7.3.5.3. Product benchmarking
7.3.5.4. Strategic initiatives
7.3.6. Abbott
7.3.6.1. Company overview
7.3.6.2. Financial performance
7.3.6.3. Product benchmarking
7.3.6.4. Strategic initiatives
7.3.7. QuidelOrtho Corporation
7.3.7.1. Company overview
7.3.7.2. Financial performance
7.3.7.3. Product benchmarking
7.3.7.4. Strategic initiatives
7.3.8. Thermo Fisher Scientific Inc.
7.3.8.1. Company overview
7.3.8.2. Financial performance
7.3.8.3. Product benchmarking
7.3.8.4. Strategic initiatives
7.3.9. Bio-Rad Laboratories, Inc.
7.3.9.1. Company overview
7.3.9.2. Financial performance
7.3.9.3. Product benchmarking
7.3.9.4. Strategic initiatives
7.3.10. F. Hoffmann-La Roche Ltd.
7.3.10.1. Company overview
7.3.10.2. Financial performance
7.3.10.3. Product benchmarking
7.3.10.4. Strategic initiatives
7.3.11. BIOMЙRIEUX
7.3.11.1. Company overview
7.3.11.2. Financial performance
7.3.11.3. Product benchmarking
7.3.11.4. Strategic initiatives
7.3.12. DiaSorin S.p.A.
7.3.12.1. Company overview
7.3.12.2. Financial performance
7.3.12.3. Product benchmarking
7.3.12.4. Strategic initiatives
7.3.13. Merck KGaA
7.3.13.1. Company overview
7.3.13.2. Financial performance
7.3.13.3. Product benchmarking
7.3.13.4. Strategic initiatives
7.3.14. Coris BioConcept
7.3.14.1. Company overview
7.3.14.2. Financial performance
7.3.14.3. Product benchmarking
7.3.14.4. Strategic initiatives
7.3.15. Siemens Healthineers AG
7.3.15.1. Company overview
7.3.15.2. Financial performance
7.3.15.3. Product benchmarking
7.3.15.4. Strategic initiatives
7.3.16. Quest Diagnostics Incorporated
7.3.16.1. Company overview
7.3.16.2. Financial performance
7.3.16.3. Product benchmarking
7.3.16.4. Strategic initiatives
1.1. Market Segmentation & Scope
1.2. Segment Definitions
1.2.1. Product
1.2.2. End use
1.2.3. Regional scope
1.2.4. Estimates and forecasts timeline
1.3. Research Methodology
1.4. Information Procurement
1.4.1. Purchased database
1.4.2. GVR’s internal database
1.4.3. Secondary sources
1.4.4. Primary research
1.4.5. Details of primary research
1.4.5.1. Data for primary interviews in North America
1.4.5.2. Data for primary interviews in Europe
1.4.5.3. Data for primary interviews in Asia Pacific
1.4.5.4. Data for primary interviews in Latin America
1.4.5.5. Data for Primary interviews in MEA
1.5. Information or Data Analysis
1.5.1. Data analysis models
1.6. Market Formulation & Validation
1.7. Model Details
1.7.1. Commodity flow analysis (Model 1)
1.7.2. Approach 1: Commodity flow approach
1.7.3. Volume price analysis (Model 2)
1.7.4. Approach 2: Volume price analysis
1.8. List of Secondary Sources
1.9. List of Primary Sources
1.10. Objectives
CHAPTER 2. EXECUTIVE SUMMARY
2.1. Market Outlook
2.2. Segment Outlook
2.2.1. Product and End use outlook
2.2.2. Regional outlook
2.3. Competitive Insights
CHAPTER 3. RESPIRATORY SYNCYTIAL VIRUS DIAGNOSTICS MARKET VARIABLES, TRENDS & SCOPE
3.1. Market Lineage Outlook
3.1.1. Parent market outlook
3.1.2. Related/ancillary market outlook
3.2. Market Dynamics
3.2.1. Market driver analysis
3.2.1.1. Rising prevalence of Respiratory Syncytial Virus (RSV) Infections
3.2.1.2. Advancements in diagnostics technologies
3.2.1.3. Growing awareness and healthcare spending
3.2.2. Market restraint analysis
3.2.2.1. High cost associated with advanced diagnostic tests
3.2.2.2. Lack of awareness in developing reagions
3.3. Respiratory Syncytial Virus Diagnostics Market Analysis Tools
3.3.1. Industry Analysis - Porter’s
3.3.1.1. Supplier power
3.3.1.2. Buyer power
3.3.1.3. Substitution threat
3.3.1.4. Threat of new entrant
3.3.1.5. Competitive rivalry
3.3.2. PESTEL Analysis
3.3.2.1. Political landscape
3.3.2.2. Economic landscape
3.3.2.3. Technological landscape
3.3.2.4. Social landscape
3.3.2.5. Environmental landscape
CHAPTER 4. RESPIRATORY SYNCYTIAL VIRUS DIAGNOSTICS MARKET: PRODUCT ESTIMATES & TREND ANALYSIS
4.1. Global Respiratory Syncytial Virus Diagnostics Market: Product Dashboard
4.2. Global Respiratory Syncytial Virus Diagnostics Market: Product Movement Analysis
4.3. Global Respiratory Syncytial Virus Diagnostics Market by Product , Revenue
4.4. Direct Fluorescent Antibody (DFA) Method
4.5. Rapid Antigen Diagnostic Test (RADTs)
4.5.1. Rapid Antigen Diagnostic Test (RADTs) market estimates and forecasts 2018 to 2030 (USD Billion)
4.6. Molecular Diagnostics
4.6.1. Molecular diagnostics market estimates and forecasts 2018 to 2030 (USD Billion)
4.7. Chromatographic Immunoassay
4.7.1. Chromatography immunoassay market estimates and forecasts 2018 to 2030 (USD Billion)
4.7.2. Gravity Driven Test
4.7.2.1. Gravity driven test market estimates and forecasts 2018 to 2030 (USD Billion)
4.7.3. Oligochromatography (OC)
4.7.3.1. Oligochromatography (OC) market estimates and forecasts 2018 to 2030 (USD Billion)
4.8. Diagnostic Imaging
4.8.1. Diagnostic imaging market estimates and forecasts 2018 to 2030 (USD Billion)
4.9. Gel Microdroplets
4.9.1. Gel microdroplets market estimates and forecasts 2018 to 2030 (USD Billion)
4.10. Flow Cytometry
4.10.1. Flow cytometry market estimates and forecasts 2018 to 2030 (USD Billion)
4.11. Others
4.11.1. Others market estimates and forecasts 2018 to 2030 (USD Billion)
CHAPTER 5. RESPIRATORY SYNCYTIAL VIRUS DIAGNOSTICS MARKET: END USE ESTIMATES & TREND ANALYSIS
5.1. Global Respiratory Syncytial Virus Diagnostics Market: End use Dashboard
5.2. Global Respiratory Syncytial Virus Diagnostics Market: End use Movement Analysis
5.3. Global Respiratory Syncytial Virus Diagnostics Market by End use, Revenue
5.4. Hospitals
5.4.1. Hospitals market estimates and forecasts 2018 to 2030 (USD Billion)
5.5. Laboratory
5.5.1. Laboratory market estimates and forecasts 2018 to 2030 (USD Billion)
5.6. Clinics
5.6.1. Clinics market estimates and forecasts 2018 to 2030 (USD Billion)
5.7. Others
5.7.1. Others market estimates and forecasts 2018 to 2030 (USD Billion)
CHAPTER 6. RESPIRATORY SYNCYTIAL VIRUS DIAGNOSTICS MARKET: REGIONAL ESTIMATES & TREND ANALYSIS BY TYPE, TUBE MATERIAL, APPLICATION, AND END USE
6.1. Regional Dashboard
6.2. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
6.3. North America
6.3.1. U.S.
6.3.1.1. Key country dynamics
6.3.1.2. Regulatory framework/ reimbursement structure
6.3.1.3. Competitive scenario
6.3.1.4. U.S. market estimates and forecasts 2018 to 2030 (USD Billion)
6.3.2. Canada
6.3.2.1. Key country dynamics
6.3.2.2. Regulatory framework/ reimbursement structure
6.3.2.3. Competitive scenario
6.3.2.4. Canada market estimates and forecasts 2018 to 2030 (USD Billion)
6.3.3. Mexico
6.3.3.1. Key country dynamics
6.3.3.2. Regulatory framework/ reimbursement structure
6.3.3.3. Competitive scenario
6.3.3.4. Mexico market estimates and forecasts 2018 to 2030 (USD Billion)
6.4. Europe
6.4.1. UK
6.4.1.1. Key country dynamics
6.4.1.2. Regulatory framework/ reimbursement structure
6.4.1.3. Competitive scenario
6.4.1.4. UK market estimates and forecasts 2018 to 2030 (USD Billion)
6.4.2. Germany
6.4.2.1. Key country dynamics
6.4.2.2. Regulatory framework/ reimbursement structure
6.4.2.3. Competitive scenario
6.4.2.4. Germany market estimates and forecasts 2018 to 2030 (USD Billion)
6.4.3. France
6.4.3.1. Key country dynamics
6.4.3.2. Regulatory framework/ reimbursement structure
6.4.3.3. Competitive scenario
6.4.3.4. France market estimates and forecasts 2018 to 2030 (USD Billion)
6.4.4. Italy
6.4.4.1. Key country dynamics
6.4.4.2. Regulatory framework/ reimbursement structure
6.4.4.3. Competitive scenario
6.4.4.4. Italy market estimates and forecasts 2018 to 2030 (USD Billion)
6.4.5. Spain
6.4.5.1. Key country dynamics
6.4.5.2. Regulatory framework/ reimbursement structure
6.4.5.3. Competitive scenario
6.4.5.4. Spain market estimates and forecasts 2018 to 2030 (USD Billion)
6.4.6. Norway
6.4.6.1. Key country dynamics
6.4.6.2. Regulatory framework/ reimbursement structure
6.4.6.3. Competitive scenario
6.4.6.4. Norway market estimates and forecasts 2018 to 2030 (USD Billion)
6.4.7. Sweden
6.4.7.1. Key country dynamics
6.4.7.2. Regulatory framework/ reimbursement structure
6.4.7.3. Competitive scenario
6.4.7.4. Sweden market estimates and forecasts 2018 to 2030 (USD Billion)
6.4.8. Denmark
6.4.8.1. Key country dynamics
6.4.8.2. Regulatory framework/ reimbursement structure
6.4.8.3. Competitive scenario
6.4.8.4. Denmark market estimates and forecasts 2018 to 2030 (USD Billion)
6.5. Asia Pacific
6.5.1. Japan
6.5.1.1. Key country dynamics
6.5.1.2. Regulatory framework/ reimbursement structure
6.5.1.3. Competitive scenario
6.5.1.4. Japan market estimates and forecasts 2018 to 2030 (USD Billion)
6.5.2. China
6.5.2.1. Key country dynamics
6.5.2.2. Regulatory framework/ reimbursement structure
6.5.2.3. Competitive scenario
6.5.2.4. China market estimates and forecasts 2018 to 2030 (USD Billion)
6.5.3. India
6.5.3.1. Key country dynamics
6.5.3.2. Regulatory framework/ reimbursement structure
6.5.3.3. Competitive scenario
6.5.3.4. India market estimates and forecasts 2018 to 2030 (USD Billion)
6.5.4. Australia
6.5.4.1. Key country dynamics
6.5.4.2. Regulatory framework/ reimbursement structure
6.5.4.3. Competitive scenario
6.5.4.4. Australia market estimates and forecasts 2018 to 2030 (USD Billion)
6.5.5. South Korea
6.5.5.1. Key country dynamics
6.5.5.2. Regulatory framework/ reimbursement structure
6.5.5.3. Competitive scenario
6.5.5.4. South Korea market estimates and forecasts 2018 to 2030 (USD Billion)
6.5.6. Thailand
6.5.6.1. Key country dynamics
6.5.6.2. Regulatory framework/ reimbursement structure
6.5.6.3. Competitive scenario
6.5.6.4. Thailand market estimates and forecasts 2018 to 2030 (USD Billion)
6.6. Latin America
6.6.1. Brazil
6.6.1.1. Key country dynamics
6.6.1.2. Regulatory framework/ reimbursement structure
6.6.1.3. Competitive scenario
6.6.1.4. Brazil market estimates and forecasts 2018 to 2030 (USD Billion)
6.6.2. Argentina
6.6.2.1. Key country dynamics
6.6.2.2. Regulatory framework/ reimbursement structure
6.6.2.3. Competitive scenario
6.6.2.4. Argentina market estimates and forecasts 2018 to 2030 (USD Billion)
6.7. MEA
6.7.1. South Africa
6.7.1.1. Key country dynamics
6.7.1.2. Regulatory framework/ reimbursement structure
6.7.1.3. Competitive scenario
6.7.1.4. South Africa market estimates and forecasts 2018 to 2030 (USD Billion)
6.7.2. Saudi Arabia
6.7.2.1. Key country dynamics
6.7.2.2. Regulatory framework/ reimbursement structure
6.7.2.3. Competitive scenario
6.7.2.4. Saudi Arabia market estimates and forecasts 2018 to 2030 (USD Billion)
6.7.3. UAE
6.7.3.1. Key country dynamics
6.7.3.2. Regulatory framework/ reimbursement structure
6.7.3.3. Competitive scenario
6.7.3.4. UAE market estimates and forecasts 2018 to 2030 (USD Billion)
6.7.4. Kuwait
6.7.4.1. Key country dynamics
6.7.4.2. Regulatory framework/ reimbursement structure
6.7.4.3. Competitive scenario
6.7.4.4. Kuwait market estimates and forecasts 2018 to 2030 (USD Billion)
CHAPTER 7. COMPETITIVE LANDSCAPE
7.1. Recent Developments & Impact Analysis, By Key Market Participants
7.2. Company/Competition Categorization
7.3. Vendor Landscape
7.3.1. List of key distributors and channel partners
7.3.2. Key customers
7.3.3. Key company market share analysis, 2024
7.3.4. BD (Becton, Dickinson, and Company)
7.3.4.1. Company overview
7.3.4.2. Financial performance
7.3.4.3. Product benchmarking
7.3.4.4. Strategic initiatives
7.3.5. Novartis AG
7.3.5.1. Company overview
7.3.5.2. Financial performance
7.3.5.3. Product benchmarking
7.3.5.4. Strategic initiatives
7.3.6. Abbott
7.3.6.1. Company overview
7.3.6.2. Financial performance
7.3.6.3. Product benchmarking
7.3.6.4. Strategic initiatives
7.3.7. QuidelOrtho Corporation
7.3.7.1. Company overview
7.3.7.2. Financial performance
7.3.7.3. Product benchmarking
7.3.7.4. Strategic initiatives
7.3.8. Thermo Fisher Scientific Inc.
7.3.8.1. Company overview
7.3.8.2. Financial performance
7.3.8.3. Product benchmarking
7.3.8.4. Strategic initiatives
7.3.9. Bio-Rad Laboratories, Inc.
7.3.9.1. Company overview
7.3.9.2. Financial performance
7.3.9.3. Product benchmarking
7.3.9.4. Strategic initiatives
7.3.10. F. Hoffmann-La Roche Ltd.
7.3.10.1. Company overview
7.3.10.2. Financial performance
7.3.10.3. Product benchmarking
7.3.10.4. Strategic initiatives
7.3.11. BIOMЙRIEUX
7.3.11.1. Company overview
7.3.11.2. Financial performance
7.3.11.3. Product benchmarking
7.3.11.4. Strategic initiatives
7.3.12. DiaSorin S.p.A.
7.3.12.1. Company overview
7.3.12.2. Financial performance
7.3.12.3. Product benchmarking
7.3.12.4. Strategic initiatives
7.3.13. Merck KGaA
7.3.13.1. Company overview
7.3.13.2. Financial performance
7.3.13.3. Product benchmarking
7.3.13.4. Strategic initiatives
7.3.14. Coris BioConcept
7.3.14.1. Company overview
7.3.14.2. Financial performance
7.3.14.3. Product benchmarking
7.3.14.4. Strategic initiatives
7.3.15. Siemens Healthineers AG
7.3.15.1. Company overview
7.3.15.2. Financial performance
7.3.15.3. Product benchmarking
7.3.15.4. Strategic initiatives
7.3.16. Quest Diagnostics Incorporated
7.3.16.1. Company overview
7.3.16.2. Financial performance
7.3.16.3. Product benchmarking
7.3.16.4. Strategic initiatives
